LONA

MKT CAP:$32M

LeonaBio, Inc.

Market Cap

$32M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$8.62+$1.66 (+23.85%)

Apr 23, 2026

Company Details

LeonaBio, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis,...

CEO

Mark J. Litton

IPO Date

Sep 18, 2020

Website

leonabio.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$106M

EPS (Diluted)

-$24.70

Free Cash Flow

-$46M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 8, 2026

PENDING

FY 2025

Mar 31, 2026

$0EPS -$24.70

Q4 2025

Mar 31, 2026

$0EPS -$18.94

Q3 2025

Nov 6, 2025

$0EPS -$1.68

Q2 2025

Aug 7, 2025

$0EPS -$1.78

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$23M
Q2 22	$0	$0	-$24M
Q3 22	$0	$0	-$24M
Q4 22	$0	$0	-$33M
Q1 23	$0	$0	-$30M
Q2 23	$0	$0	-$32M
Q3 23	$0	$0	-$35M
Q4 23	$0	$0	-$29M
Q1 24	$0	-$242.0K	-$28M
Q2 24	$0	-$242.0K	-$28M
Q3 24	$0	$0	-$30M
Q4 24	$0	$0	-$16M
Q1 25	$0	-$243.0K	-$10M
Q2 25	$0	-$200.0K	-$7M
Q3 25	$0	-$243.0K	-$7M
Q4 25	$0	-$68M	-$79M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$17M	-$17M
Q2 22	-$19M	-$19M
Q3 22	-$22M	-$22M
Q4 22	-$16M	-$16M
Q1 23	-$26M	-$26M
Q2 23	-$24M	-$24M
Q3 23	-$24M	-$24M
Q4 23	-$26M	-$26M
Q1 24	-$26M	-$26M
Q2 24	-$22M	-$22M
Q3 24	-$23M	-$23M
Q4 24	-$26M	-$26M
Q1 25	-$15M	-$15M
Q2 25	-$7M	-$7M
Q3 25	-$5M	-$5M
Q4 25	-$19M	-$19M

Capital Expenditures

Quarter	CapEx
Q1 22	$745.0K
Q2 22	$151.0K
Q3 22	$244.0K
Q4 22	$1.0K
Q1 23	$241.0K
Q2 23	$33.0K
Q3 23	$30.0K
Q4 23	$0
Q1 24	$5.0K
Q2 24	$28.0K
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+116.9%
Q2 22	—	+41.7%
Q3 22	—	+35.4%
Q4 22	—	+75.3%
Q1 23	—	+27.3%
Q2 23	—	+34.2%
Q3 23	—	+45.2%
Q4 23	—	-11.9%
Q1 24	—	-7.0%
Q2 24	—	-11.4%
Q3 24	—	-15.5%
Q4 24	—	-46.4%
Q1 25	—	-65.6%
Q2 25	—	-74.0%
Q3 25	—	-76.8%
Q4 25	—	+404.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$0	—
Q2 22	$0	—
Q3 22	$2M	—
Q4 22	$0	—
Q1 23	$0	—
Q2 23	$3M	—
Q3 23	$2M	—
Q4 23	$2M	—
Q1 24	$3M	—
Q2 24	$3M	—
Q3 24	$3M	—
Q4 24	$2M	—
Q1 25	$2M	—
Q2 25	$2M	—
Q3 25	$1M	—
Q4 25	$1M	—

OpEx Breakdown

Quarter	R&D	G&A
Q1 22	$14M	$9M
Q2 22	$15M	$9M
Q3 22	$17M	$7M
Q4 22	$15M	$8M
Q1 23	$21M	$8M
Q2 23	$22M	$10M
Q3 23	$27M	$8M
Q4 23	$24M	$7M
Q1 24	$21M	$6M
Q2 24	$22M	$6M
Q3 24	$18M	$8M
Q4 24	$9M	$6M
Q1 25	$4M	$5M
Q2 25	$4M	$4M
Q3 25	$3M	$4M
Q4 25	$7M	$4M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$118M	$146M	$264M
Q2 22	$95M	$157M	$252M
Q3 22	$87M	$134M	$221M
Q4 22	$96M	$104M	$200M
Q1 23	$105M	$81M	$186M
Q2 23	$114M	$72M	$186M
Q3 23	$110M	$63M	$173M
Q4 23	$91M	$57M	$147M
Q1 24	$78M	$44M	$122M
Q2 24	$74M	$18M	$92M
Q3 24	$69M	$0	$69M
Q4 24	$48M	$3M	$51M
Q1 25	$26M	$10M	$37M
Q2 25	$20M	$10M	$30M
Q3 25	$21M	$4M	$25M
Q4 25	$69M	$19M	$88M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	4M	+0.6%	+5.1%
Q2 22	4M	+0.2%	+1.2%
Q3 22	4M	+0.4%	+1.4%
Q4 22	4M	+0.0%	+1.2%
Q1 23	4M	+0.3%	+0.9%
Q2 23	4M	+0.2%	+0.9%
Q3 23	4M	+0.1%	+0.6%
Q4 23	4M	+0.1%	+0.8%
Q1 24	4M	+0.6%	+1.0%
Q2 24	4M	+0.2%	+1.0%
Q3 24	4M	+0.4%	+1.2%
Q4 24	4M	-0.1%	+1.0%
Q1 25	4M	+1.5%	+1.9%
Q2 25	4M	+0.1%	+1.9%
Q3 25	4M	+0.9%	+2.4%
Q4 25	4M	+8.4%	+11.1%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	35
Q2 22	$0	35
Q3 22	$0	35
Q4 22	$0	64
Q1 23	$0	64
Q2 23	$0	64
Q3 23	$0	64
Q4 23	$0	67
Q1 24	$0	67
Q2 24	$0	67
Q3 24	$0	67
Q4 24	$0	26
Q1 25	$0	26
Q2 25	$0	26
Q3 25	$0	26
Q4 25	$0	19

Revenue / Employee